Leukotriene B₄, an Endogenous Stimulator of the Innate Immune Response against Pathogens

Manon Le Bel · Alexandre Brunet · Jean Gosselin

Laboratory of Innate Immunology, Centre Hospitalier Universitaire de Québec, and Department of Molecular Medicine, Laval University, Quebec City, Que., Canada

Key Words

Leukotriene B₄ · Neutrophils · Toll-like receptor · Antimicrobial peptides · Host defense · Viral infection · Macrophages

Abstract

Leukotriene B₄ (LTB₄) is an endogenous lipid mediator of inflammation derived from arachidonic acid by the sequential action of cytosolic phospholipase A₂ and 5-lipoxygenase. This mediator was initially recognized for its involvement in the recruitment of neutrophils. However, in the last decade, LTB₄ has been clearly demonstrated to play a significant role in the control of microbial infections through its ability to activate host innate defenses. In this review, we will focus on the modulator effects of LTB₄ on the innate defenses and discuss its therapeutic potential against viral pathogens.

Copyright © 2013 S. Karger AG, Basel

Introduction

Leukotrienes (LTs) are a family of mediators known to exert a multitude of biologic effects that contribute to enhance the inflammatory response. LTs are generated from the liberation of arachidonic acid through the action of cytosolic phospholipase A₂ and 5-lipoxygenase (5-LO),

which is expressed in all cells of myeloid origin. Upon an increase in intracellular calcium, 5-LO translocates to the nuclear membrane, which requires the action of the membrane anchor 5-LO-activating protein [1]. This process gives rise to the formation of LTA₄, which is converted to LTB₄ through the action of LTA₄ hydrolase [2]. LTA₄ can also be converted to LTC₄ by LTC₄ synthase and constitutes the precursor of other cysteinyl LTs named LTD₄ and LTE₄.

First identified in neutrophils following incubation with arachidonic acid [3], LTB₄ was also shown to be produced by other cell types. In fact, synthesis of LTB₄ has been demonstrated in human alveolar macrophages stimulated with zymosan or ionophore A23187 [4, 5]. Bronchial epithelial cells and fibroblasts are also able to generate LTB₄ [6, 7], indicating that these cells may contribute to the inflammatory response in lungs. Peritoneal macrophages, monocytes and dendritic cells may produce LTB₄ in response to several stimuli including N-formyl-methionyl-leucyl-phenylalanine peptide, zymosan particles, complement complex, bacterial components and endotoxins [8–10].

LTB₄ signaling is achieved through BLT receptors belonging to the G protein-coupled receptor family. In mammalian cells, two LTB₄ receptors are expressed, i.e. the high-affinity BLT1 receptor and the low-affinity BLT2 receptor. BLT1 is mainly expressed by leukocytes, par-

ticularly neutrophils and eosinophils, whereas BLT2 is expressed ubiquitously, with increased expression in lymphoid organs [11]. The chemoattractive properties of LTB₄ as well as its proinflammatory effects are mainly mediated by the BLT1 receptor. Following binding to its receptor, an increase in Ca²⁺ mobilization is observed and downstream signaling molecules are activated. LTB₄ activates several kinase cascades leading to the transcription of cytokine genes. Two important but distinct signaling pathways are sensitive to LTB₄ action, one leading to the translocation of nuclear factor (NF)-κB, while the other activates members of the mitogen-activated protein kinase (MAPK) family such as p38, c-JUN kinase and extracellular signal-regulated kinases 1/2, leading to the activation of the transcription factor activated protein-1 [12–14]. In addition, LTB₄ was shown to induce neutrophil activation and degranulation through its effects on the β isoform of phosphoinositide 3-kinase and the Src kinase Yes, respectively [15, 16]. LTB₄ activates the GTPase Rac and Rac-extracellular signal-regulated kinase, two signaling molecules that contribute to phagocytosis and chemotaxis [17]. These studies demonstrate that LTB₄ can influence several kinases involved in different downstream signaling pathways associated with the aforementioned biological processes. Therefore, it is not surprising that LTB₄ can exert pleiotropic actions on host cells.

LTB₄ and the Inflammatory Response

Inflammation is a complex physiological response initiated following pathogen recognition and tissue injuries. In the early phase of inflammation, activation of resident macrophages and other immune cells induces the release of cytokines and chemokines that subsequently recruit inflammatory cells to the tissue. During infection, inflammation further correlates with increased transport of pathogens and antigen-presenting cells from the infected tissue to the lymphoid organs. This gives rise to lymphocyte activation and initiation of adaptive immunity characterized by antibody production and effector cell recruitment to the site of infection.

The early phase of the immune response is characterized, as mentioned above, by the rapid recruitment of effector cells and the release of cellular mediators that trigger the onset of the immune response. In this process, LTB₄ acts as a mediator that exerts a central role on inflammatory cells through its chemoattractant properties. This LT was initially recognized as a cellular chemoat-

tractant released from polymorphonuclear leukocytes [18]. This was based on studies showing that intravenous injections of LTB₄ in rabbits resulted in a prompt increase in blood neutrophils, and intradermal injection of LTB₄ leads to an accumulation of neutrophils at the site of injection [19]. The capacity of LTB₄ to recruit effector cells is not limited to neutrophils. The chemoattractant activity of LTB₄ was also demonstrated for monocytes, macrophages, dendritic cells, eosinophils and effector T cells [20–22]. Of potential importance, LTB₄ induces recruitment of CD4 and CD8 effector T cells as well as T helper type 1 and T helper type 2 cells to inflamed tissue [23, 24], providing a link between innate and adaptive immune responses. Early recruitment of activated immune cells during the onset of inflammation constitutes one of the main mechanisms through which LTB₄ modulates the inflammatory process.

Following their entry into peripheral tissue, the recruited immune cells will engage in the inflammation process by secreting cytokines and chemokines, which also contribute to promote inflammation. Evidence shows that LTB₄ is active in this process and enhances the production of several inflammatory mediators such as interleukin (IL)-2 and IL-5 by T cells. LTB₄ was also found to increase the sensitivity of T lymphocytes to IL-2, a mediator essential for T cell proliferation. In fact, *in vitro* assays showed that lymphocytes that had been incubated with LTB₄ for 24 h were more responsive to IL-2, showing that LTB₄ increased the sensitivity of cytotoxic lymphocytes to IL-2 activation [25]. This increased activity was attributed to an upregulation of IL-2 receptor β expression, which is mostly expressed on natural killer and CD8 T cells. Similarly, LTB₄ induces rapid, dose-dependent IL-5 production in T cells [26]. These cytokines are produced by T helper type 1 and type 2 cells and together contribute to activation of the immune response, characterized by the recruitment, proliferation and activation of immune cells.

LTB₄ increases the production of IL-1 (α/β), IL-6 and chemokine (C-C motif) ligand 2 (monocyte chemoattractant protein-1) in monocytes and the release of IL-8 by neutrophils. Production of IL-1 by human monocytes stimulated with lipopolysaccharide (LPS) was potentiated in LTB₄-pretreated cells [27]. This mediator is also considered a potent inducer of chemokine (C-C motif) ligand 2 (monocyte chemoattractant protein-1) secretion in monocytes [28]. Similarly, LTB₄ induces the release of chemokine (C-X-C motif) ligand 8 (IL-8) by neutrophils and potentiates IL-8 secretion in response to various stimuli [29, 30]. Overall, the role of LTB₄ in the inflammatory re-

sponse can be either directly associated with the recruitment of inflammatory cells or indirectly with its capacity to induce secretion of inflammatory mediators by surrounding cells.

Being associated with various diseases, including chronic pulmonary disorders, drugs targeting LTs were developed as anti-inflammatory medications over the last 20 years [31]. Cysteinyl LT is especially suspected to play a role in asthma, and LTB₄, being recognized as a potent chemoattractant for leukocytes, was also associated with the inflammatory response. Due to the physiological functions it exerts on cells, LTB₄ has long been considered a detrimental mediator of inflammation.

From a clinical perspective, evidence suggests that LTB₄ plays a key role in various inflammatory diseases, especially in lung diseases such as asthma or chronic obstructive pulmonary disease. Increased levels of LTB₄ have been identified in the sputum, plasma and bronchoalveolar lavage fluid of asthmatic patients [32–34]. The levels of LTB₄ were also found to be increased in the exhaled breath condensate of chronic obstructive pulmonary disease patients [35]. Since bronchial epithelial cells and lung fibroblasts are able to secrete LTB₄, it was assumed that in these pathological conditions, LTB₄ could exacerbate inflammatory symptoms through the recruitment and accumulation of inflammatory cells in the respiratory tract along with the secretion of inflammatory cytokines. Nevertheless, new findings on the role of LTB₄ in controlling viral infection and the mechanisms associated with such effects provide new insights into the beneficial role of LTB₄ as a regulator of the innate response.

LTB₄ Is an Activator of the Innate Immune Response

LTB₄ Contributes to the Control of Viral Infection

Release of eicosanoids like LTs is known to influence many biological processes. Their regulatory roles in inflammation and immune defense against viral infections are of particular interest [reviewed in 36], especially with regard to LTB₄, which was reported to exert appealing activity on innate defenses against pathogens. In fact, besides its association with the inflammatory process, several reports from the last decade highlight the involvement of LTB₄ in the activation of innate immune defense against viral infection. The first evidence of the antiviral activity of LTB₄ was demonstrated against Epstein-Barr virus (EBV) and herpes simplex type 1 virus, two viruses of the herpes family [37, 38]. In vitro treatment of EBV-infected human peripheral blood mononuclear cells with

LTB₄ was found to strongly reduce the B cell growth-transforming ability of EBV as reflected by the reduced expression of Epstein-Barr nuclear antigen in infected cells. Similar results were also obtained in Vero cell cultures infected with herpes simplex type 1 virus, in which the percentage of infected cells was also affected by the addition of exogenous LTB₄. Interestingly, in these experiments, the antiviral potency of LTB₄ was comparable to the inhibitory effect of acyclovir, a drug widely used for the treatment of herpes infection in humans [37, 38]. These initial experiments clearly demonstrated that treatment with LTB₄ can control viral infection. In addition, treatment of cell cultures with LTB₄ did not block viral entry into the cell, suggesting that it may act on intracellular components to suppress viral replication. More recently, EBV-infected cord blood cell cultures were used to show that LTB₄ contributes to suppress the B cell transformation induced by EBV [39, 40]. The authors demonstrated that inhibition of B cell proliferation by LTB₄ was associated with activation of effector T cells.

The potential role of LTB₄ in viral infection was further demonstrated in vivo in mice infected with murine cytomegalovirus (MCMV) [41]. Intravenous administration of LTB₄ to mice infected with a lethal dose of MCMV significantly reduced the mortality rate as compared to the placebo group. Body weight and temperature data were also in accordance with the survival rate of mice treated with LTB₄. Daily LTB₄ treatment of mice infected with a sublethal dose of MCMV was also found to reduce viral loads titrated in the salivary glands of the mice. Considering that CMV reactivation can be observed in humans, especially in those receiving immunosuppressive therapies, studies aimed at evaluating the protective role of LTB₄ against viral reactivation were also performed. Using an allogeneic bone marrow transplantation model, administration of LTB₄ was found to prevent MCMV reactivation in latently infected mice. LTB₄-associated effects were confirmed in 5-LO-deficient mice infected with MCMV and in wild-type infected mice pretreated with MK-886, an inhibitor of 5-LO-activating protein. In these animals, inhibition of LT synthesis results in a significant increase in the viral load in salivary glands, supporting a role for endogenous LTB₄ in the host defense against CMV infection.

The potential efficacy of LTB₄ to activate the host defense against viral infection was also tested with influenza virus, a single-stranded RNA virus. Daily administration of LTB₄ to influenza-infected mice potentiated the reduction of lung viral loads as opposed to mice treated with a placebo [42]. Results from this study indicate that recruit-

ment of neutrophils to the lungs is an important event in controlling influenza infection, which correlates with a decrease in viral load and restored lung architecture. While not specifically identifying LTB₄, another study investigating the role of LTs in acute vesicular stomatitis virus encephalitis documented the protective role of LTs in viral infection [43]. The authors demonstrated that pharmacologic or genetic inactivation of the 5-LO enzyme correlates with a higher viral titer in the brain during early phases of infection. Interestingly, other investigations suggested that impairment of LT synthesis in acquired immunodeficiency syndrome might contribute to the observed susceptibility to opportunistic infections, supporting the beneficial effects of LTs in innate defense against viruses [44, 45]. Recently, it was shown that LTs, including LTB₄ and LTC₄, could inhibit human immunodeficiency virus type 1 (HIV-1) infection in vitro in human monocyte-derived microglia-like cells [46]. LTB₄ was demonstrated to significantly reduce viral loads in this primary cell system, suggesting a protective role in the central nervous system of HIV-infected patients.

On the other hand, it was reported that LTB₄ and LTC₄ were increased in the plasma of human T lymphotropic virus type 1-infected patients. The authors suggest that such an enhanced concentration of LTB₄ and LTC₄ could potentially contribute to the dysregulation of the immune system in neuroinflammatory disease [47]. In a second study, it was shown that human CMV infection of vascular smooth muscle cells leads to enhanced 5-LO expression, resulting in an increase in LTB₄ production [48]. This study proposed that human CMV could initiate and sustain inflammation through the control of 5-LO expression in patients with ulcerative colitis. Despite the fact that, in the specific context of infection, upregulation of the 5-LO pathway may compromise the immune response, LTB₄ is mainly associated with beneficial effects in controlling viral infections.

LTB₄ Is Involved in Antibacterial Immunity

In addition to its potential role in controlling viral infection, LTB₄ was also suggested to contribute to bacterial clearance [reviewed in 49]. The first evidence of the antibacterial role of LTB₄ was highlighted with the demonstration that intraperitoneal administration of LTB₄ resolves experimental bacterial peritonitis in mice [50]. The increased clearance of *Salmonella typhimurium* observed in these animals was proposed to occur through an enhanced bactericidal action of macrophages since this phenomenon was abrogated in animals with high susceptibility to bacterial infection. In mice deficient for the

5-LO gene, it was demonstrated that the host response to pulmonary bacterial infection was mediated by LTs. Following intratracheal *Klebsiella pneumoniae* challenge, a marked increase in LTs and neutrophils was observed in wild-type mice, whereas this response was impaired in knockout mice. This phenomenon correlated with a significant increase in lethality and bacteremia in LT-deficient animals as compared to wild-type mice [51]. The reduced capacity for bacterial clearance of LT-deficient mice was associated with a defect in the phagocytic activity of alveolar macrophages. Interestingly, such defects were overcome in vitro by treatment of macrophages with exogenous LTB₄. Similar conclusions were reached in studies using mice infected with fungal and bacterial organisms and treated with LT synthesis inhibitors, such as MK-886 and A-63162, in which reduced survival rate and bacterial clearance, respectively, were observed [52, 53]. Together, these data indicate that LTs and especially LTB₄ plays a significant role in host defense against microbial pathogens.

Innate Effector Mechanisms Activated by LTB₄ to Control Bacterial and Viral Infection

Destruction of microorganisms requires the contribution of complex intracellular mechanisms such as activation of cytotoxic systems and phagocytosis. The contribution of LTs to the modulation of antimicrobial effector functions and the role of LTB₄ in antibacterial defenses have been documented [49]. Briefly, LTB₄ modulates killing of bacteria through the synthesis of the reactive oxygen intermediate, nitric oxide, and hydrogen peroxide. LTB₄ may also regulate the release of lysosomal enzymes, cytokine production and phagocytosis, which are necessary to neutralize pathogens. These mechanisms activated by LTB₄ are summarized in table 1. Recent insights into LTB₄-activated mechanisms to control both bacterial and viral infections are discussed in the following sections.

LTB₄ Induces Release of Antimicrobial Peptides

LTB₄-induced antimicrobial peptide synthesis has been demonstrated against a diverse range of bacteria [49]. The mechanisms underlying the antiviral activity of LTB₄ are not fully understood and remain to be characterized. However, one of the known effective strategies to fight a wide range of pathogens includes the release of antimicrobial peptides. These antimicrobial peptides are known to exert broad-spectrum activity against bacteria,

Table 1. LTB₄-associated antimicrobial activity on effector cells

Cells	Antimicrobial functions	Microorganisms	References
Neutrophils	nitric oxide reactive oxygen species β-glucuronidase/lysozyme increased phagocytosis superanion production LL-37, EDN, α-defensins myeloperoxidase β-defensin-3, mEARs, CRAMP LL-37, EDN α-defensins, cathepsin G, elastase, lysozyme C, LL-37 α-defensin, MIP-1β	<i>Klebsiella pneumoniae</i> CMV CMV coronavirus, influenza, respiratory syncytial virus influenza influenza herpes simplex virus type 1/HIV HIV	[63, 64] ^a [65] ^a [66] ^a [67] ^{a, b} [68, 69] ^a [55] ^a [55] ^{a, b} [60] ^a [42] ^b [42] ^a [70] ^a [59] ^a
Eosinophils	nitric oxide superanion production NADPH oxidase activity		[64] ^a [71] ^b [72, 73] ^b
Monocytes/ macrophages	nitric oxide increased phagocytosis hydrogen peroxide NADPH oxidase activity	<i>Trypanosoma cruzi</i> <i>Trypanosoma cruzi</i> <i>Klebsiella pneumoniae</i> group A <i>Streptococcus</i> <i>Salmonella typhimurium</i> , <i>Pseudomonas aeruginosa</i> <i>Salmonella typhimurium</i> , <i>Pseudomonas aeruginosa</i> <i>Klebsiella pneumoniae</i> group A <i>Streptococcus</i>	[74] ^b [75] ^b [51, 76] ^b [77] ^{a, b} [50] ^b [50] ^b [78] ^a [77] ^{a, b}
Lymphocytes	immunoglobulin secretion increased CD23 expression reduced B cell transformation	<i>Staphylococcus aureus</i> EBV	[79] ^a [80] ^a [37] ^a [40] ^a

EDN = Eosinophil-derived neurotoxin; mEARs = mouse eosinophil-associated RNase; CRAMP = cathelicidin-related antimicrobial peptide; MIP-1β = macrophage inflammatory protein-1β; NADPH = nicotinamide adenine dinucleotide phosphate.

^a Human model. ^b Rodent model.

fungi and enveloped viruses [54]. For instance, β-defensin is known for its antibacterial properties through its membrane disruption effect and is also effective against yeast, such as *Candida albicans*. Cathelicidins are thought to neutralize LPS found on bacteria. Finally, eosinophil-derived neurotoxin and its murine homologue mouse eosinophil-associated RNase are two RNases with antiviral activity against respiratory viruses [42]. In fact, secretion of antimicrobial peptides by neutrophils was found to contribute to the antiviral activities of LTB₄ against influenza virus [42]. Indeed, treatment with LTB₄ leads to a decrease in viral load associated with increased expression of antimicrobial peptides, including β-defensin-3, mouse eosinophil-associated RNase and cathelicidin-related antimicrobial peptide, in lungs of mice infected with

influenza virus. In addition, neutrophils were considered to be essential in such production of antimicrobial peptides since in neutrophil-depleted mice, inability of LTB₄ to reduce lung influenza viral loads and induce production of antimicrobial peptides was observed. Similar effector mechanisms could be activated in humans since in vitro treatment of primary human neutrophils with LTB₄ also led to rapid secretion of multiple antimicrobial peptides, which was abrogated with a BLT1 receptor-specific antagonist [42, 55].

The LTB₄-mediated release of antimicrobial peptides was also demonstrated in infection with CMV. Treatment of CMV-infected human peripheral blood leukocytes with LTB₄ led to a reduction of viral titers, a process involving neutrophil activation and release of antimicro-

bial peptides [55]. Similar results were obtained in ex vivo experiments using neutrophils isolated from peritoneal lavage of wild-type and BLT1^{-/-} mice, supporting the role of antimicrobial peptides in anti-CMV effects mediated by LTB₄.

LTB₄ Potentiates Toll-Like Receptor Signaling

An effective immune defense against viruses is initiated following recognition of the viral components by encoded pattern recognition receptors including the Toll-like receptors (TLRs) [56]. Following binding to its receptor, LTB₄ activates signaling molecules interconnected with other cellular receptors such as TLRs. In fact, MAPK- and NF-κB-mediated cytokine production are signaling events common to BLT1 and TLRs. Therefore, we can assume that LTB₄ could influence the cell response to agonists recognized by TLRs. In this regard, Serezani et al. [57] have reported that LTB₄ amplifies NF-κB activation in macrophages stimulated with MyD88-dependent agonists. Macrophages isolated from 5-LO^{-/-} mice showed reduced production of cytokines in response to LPS and peptidoglycans, in addition to reduced p65 binding activity. Similar observations were made with macrophages isolated from BLT1^{-/-} mice, confirming the specific role of LTB₄/BLT1 in MyD88-dependent NF-κB activation. The authors concluded that the enhanced effect induced by LTB₄ on MyD88 expression and cytokine production was mediated by the activation of Janus kinase 2/signal transducer and activator of transcription 1 signaling, suggesting the action of LTB₄ on the MyD88 pathway.

In a more recent study aiming to investigate the interactions of LTB₄ with the TLR system, it was demonstrated that potentiation of cytokine release following stimulation of neutrophils with a combination of LTB₄ and TLR ligands such as lipoteichoic acid, LPS and CpG was dependent on activation of transforming growth factor-β-activated kinase 1 (TAK1), a molecule essential to the MyD88 signaling pathway [29]. LTB₄ potentiation of cytokine secretion in neutrophils stimulated with TLR ligands was suppressed by treatment with TAK1 inhibitor and also in a transfection assay with TAK1-targeting siRNA in HEK293 cells, confirming the action of LTB₄ on TAK1 activity. An interesting aspect of the LTB₄ action on MyD88 signaling is the demonstration that TAK1 and the MAPK p38 are interconnected in LTB₄-treated neutrophils. Indeed, pretreatment of neutrophils with TAK1 inhibitor was found to reduce levels of phosphorylated p38, indicating that activation of p38 by LTB₄ is dependent on TAK1. While not found to be essential, activation of the protein kinase IL-1 receptor-associated kinase 1

(IRAK1; IRAK1/4 complex) by LTB₄ may potentiate cytokine production by neutrophils stimulated with TLR agonists. Since the involvement of TLRs in early recognition of viral particles is crucial to control infection, the overall consequence of such effects of LTB₄ on MyD88 signaling may result in an effective innate response against several types of viruses. A proposed mechanism illustrating the potential interactions between LTB₄ and TLR signaling pathways in neutrophils is presented in figure 1.

Contribution of TLRs to the potentiating effect of LTB₄ on neutrophils was also evaluated. Interestingly, it was demonstrated that LTB₄ differentially modulates the expression of TLRs, depending on whether they are expressed at the cell surface or within the cell [29, 58]. It appears that LTB₄ exerts no effect on expression levels of the membrane receptors TLR2 and TLR4, nor the coreceptors TLR1 and TLR6, on neutrophils. However, LTB₄ can positively upregulate expression of intracellular TLR9 (as well as TLR7/8 mRNA levels), resulting in enhanced binding activity of its ligand. Such a dichotomy remains to be explained, but one might postulate that TLR gene expression could be differentially regulated depending on the cellular origin or the stimulus involved. Together, these results confirm that LTB₄ acts on interconnected signaling molecules to optimize an effective immune response. Moreover, we must also consider that LTB₄ may interact with multiple signaling molecules from different pathways (other than MyD88-dependent pathways) to enhance the state of activation and potentiate immune defenses. This aspect remains to be explored.

Conclusion

Although prostaglandins and LTs are for the most part associated with proinflammatory effects, the studies reviewed herein support the conclusion that LTB₄ benefits the host immune defense. The triggering of the immune response with molecules interacting with the signaling cascade of the innate defense is a very appealing avenue for the development of therapeutic approaches for the treatment of various diseases including viral infections. Investigation of LTB₄ as an 'immunoregulator' is an especially attractive approach for the development of new therapeutics since the available drugs are rather limited and in some cases may present host toxicity.

LTB₄ exerts several biological activities on the immune response, including increasing phagocytosis of microorganisms by neutrophils and macrophages, enhancement

Fig. 1. Schematic representation illustrating the effects of LTB₄ on the TLR signaling pathway and the release of antimicrobial peptides in neutrophils. With the exception of TLR3, all TLRs lead to the engagement of the MyD88-IRAK1/4-TAK1 axis, which culminates in the activation of MAPK-mediated activated protein-1 (AP-1) production or NF-κB-mediated cytokine production. Upon ligation of LTB₄ to the BLT1 receptor (BLT1R), cellular signaling intersects with downstream TAK1, which occupies a central role in the TLR signaling cascade. In the presence of TLR agonists,

LTB₄ potentiates TAK1 activation, leading to an increase in cytokine production. LTB₄ can also activate IRAK1/4, a process which is, however, dispensable to the enhancement of cytokine synthesis. LTB₄ mediates the synthesis and release of antimicrobial peptides [42, 55] through phosphoinositide 3-kinase (PI3K) and Src signaling pathways. Red arrows represent potentiating/activating effects of LTB₄. EDN = Eosinophil-derived neurotoxin; CRAMP = cathelicidin-related antimicrobial peptide; EARS = eosinophil-associated RNase.

of cell recruitment in tissues and production of inflammatory mediators. LTB₄ also induces the release of several antimicrobial peptides by neutrophils. Of particular interest are the interactions of LTB₄ with the TLR system. In fact, by acting on signaling molecules (such as TAK1) at levels shared by different immune receptors, this makes LTB₄ a promising and potentially powerful immune-modulating molecule. Such synergistic activity between

signaling cascades could thus contribute to optimize immune defense against pathogens.

Studies in humans clearly indicate that LTB₄ contributes to the regulation of the innate immune response and merits more thorough investigation. Indeed, intravenous administration of LTB₄ to humans was reported to lead to a dose-dependent plasmatic increase in α-defensins [59]. In another study performed in healthy individuals

having received nasal administration of LTB₄, increased production of myeloperoxidase and α-defensins was detected in nasal lavage fluids. In healthy volunteers infected with rhinovirus-16 and treated with LTB₄, reduced viral replication was measured as compared with controls [60]. The impact of LTB₄ on HIV-1-infected patients was also tested [61]. While subjects did not manifest any adverse effects over the trial period, this study failed to show anti-HIV activity. The failure to observe changes in CD4 counts and viral loads might be attributable to the selection criteria of the HIV-infected group. One could consider selecting a more advanced disease state characterized by a higher viral load and a lower CD4 count. In these conditions, subtle improvements in patient status might have been more apparent and translated into higher CD4 counts as well as a reduced viral load. In support of our hypothesis are the results from a previous phase II clinical trial conducted by Boehringer Ingelheim, in which an LTB₄ receptor BLT1 antagonist (BIIL 284 BS) was assessed in the treatment of cystic fibrosis [62]. This multicenter study showed that a significant proportion of adult and pediatric patients treated with this drug experienced adverse events involving pulmonary exacerbation and required hospitalization. The investigators proposed that the high potency of this inhibitor might explain the observed side effects, which probably resulted from a deficient antimicrobial immune response. This highlights the potential of LTB₄ in the regulation of the immune response.

Today, the challenge in the development of antiviral drugs is to design a molecule with high efficacy, low host

toxicity and reduced host adverse effects. Moreover, most antiviral agents are designed to treat a specific type of viral infection and usually focus on a virus-associated component. Drugs that boost the immune system without specifically interacting with critical components of the viral life cycle should be considered. This would reduce the selective pressure of virus-associated target therapeutics and would also reduce the appearance of resistant viral strains. Although the antibacterial and antiparasitic properties of LTB₄ seem promising, the future of the potential therapeutic development of this endogenous mediator lies in its antiviral properties and its potential to highlight avenues for new drug development. In addition, we must also consider that if the use of an 'immune booster' like LTB₄ can be controlled to modulate and enhance the level of immune responsiveness, it would constitute a very powerful tool to fight against various microbial infections. LTB₄ could then be used in prophylaxis to prevent infections or in therapy to boost the physiological response against pathogens. Interestingly, this endogenous molecule in combination with other antimicrobial drugs could result in synergic activity that potentiates their therapeutic efficacy.

LTB₄ is an important player in the innate immune defense against infectious microorganisms including viruses. Its 'boosting effects' on the TLR-mediated immune response invite pursuit of the development of such related molecules for the treatment of viral infections and will also be useful in the elaboration of new therapeutic strategies acting on the potentiation of the innate immune response.

References

- Dixon RA, Diehl RE, Opas E, Rands E, Vickers PJ, Evans JF, Gillard JW, Miller DK: Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. *Nature* 1990;343:282–284.
- Samuelsson B, Funk CD: Enzymes involved in the biosynthesis of leukotriene B₄. *J Biol Chem* 1989;264:19469–19472.
- Borgeat P, Samuelsson B: Transformation of arachidonic acid by rabbit polymorphonuclear leukocytes. Formation of a novel dihydroxyicosatetraenoic acid. *J Biol Chem* 1979;254:2643–2646.
- Brown GP, Monick MM, Hunninghake GW: Human alveolar macrophage arachidonic acid metabolism. *Am J Physiol* 1988;254:C809–C815.
- Dent G, Rabe KF, Magnussen H: Augmentation of human neutrophil and alveolar macrophage LTB₄ production by N-acetylcysteine: role of hydrogen peroxide. *Br J Pharmacol* 1997;122:758–764.
- Jame AJ, Lackie PM, Cazaly AM, Sayers I, Penrose JF, Holgate ST, Sampson AP: Human bronchial epithelial cells express an active and inducible biosynthetic pathway for leukotrienes B₄ and C₄. *Clin Exp Allergy* 2007;37:880–892.
- James AJ, Penrose JF, Cazaly AM, Holgate ST, Sampson AP: Human bronchial fibroblasts express the 5-lipoxygenase pathway. *Respir Res* 2006;7:102.
- Palmer RM, Salmon JA: Release of leukotriene B₄ from human neutrophils and its relationship to degranulation induced by N-formyl-methionyl-leucyl-phenylalanine, serum-treated zymosan and the ionophore A23187. *Immunology* 1983;50:65–73.
- Seeger W, Suttorp N, Hellwig A, Bhakdi S: Noncytolytic terminal complement complexes may serve as calcium gates to elicit leukotriene B₄ generation in human polymorphonuclear leukocytes. *J Immunol* 1986;137:1286–1293.
- Claesson HE, Lindgren JA, Gustafsson B: Opsonized bacteria stimulate leukotriene synthesis in human leukocytes. *Biochim Biophys Acta* 1985;836:361–367.
- Huang WW, Garcia-Zepeda EA, Sauty A, Oettgen HC, Rothenberg ME, Luster AD: Molecular and biological characterization of the murine leukotriene B₄ receptor expressed on eosinophils. *J Exp Med* 1998;188:1063–1074.
- Huang R, Lian JP, Robinson D, Badwey JA: Neutrophils stimulated with a variety of chemoattractants exhibit rapid activation of p21-activated kinases (Paks): separate signals are required for activation and inactivation of paks. *Mol Cell Biol* 1998;18:7130–7138.

- 13 Sanchez-Galan E, Gomez-Hernandez A, Vidal C, Martin-Ventura JL, Blanco-Colio LM, Munoz-Garcia B, Ortega L, Egido J, Tunon J: Leukotriene B4 enhances the activity of nuclear factor-kappaB pathway through BLT1 and BLT2 receptors in atherosclerosis. *Cardiovasc Res* 2009;81:216–225.
- 14 Tong WG, Ding XZ, Talamonti MS, Bell RH, Adrian TE: LTB4 stimulates growth of human pancreatic cancer cells via MAPK and PI-3 kinase pathways. *Biochem Biophys Res Commun* 2005;335:949–956.
- 15 Gaudreault E, Thompson C, Stankova J, Rola-Pleszczynski M: Involvement of BLT1 endocytosis and Yes kinase activation in leukotriene B4-induced neutrophil degranulation. *J Immunol* 2005;174:3617–3625.
- 16 Kulkarni S, Sitaru C, Jakus Z, Anderson KE, Damoulakis G, Davidson K, Hirose M, Juss J, Oxley D, Chessa TA, Ramadani F, Guillou H, Segonds-Pichon A, Fritsch A, Jarvis GE, Okkenhaug K, Ludwig R, Zillikens D, Mocsai A, Vanhaesebroeck B, Stephens LR, Hawkins PT: PI3Kbeta plays a critical role in neutrophil activation by immune complexes. *Sci Signal* 2011;4:ra23.
- 17 Woo CH, You HJ, Cho SH, Eom YW, Chun JS, Yoo YJ, Kim JH: Leukotriene B(4) stimulates Rac-ERK cascade to generate reactive oxygen species that mediates chemotaxis. *J Biol Chem* 2002;277:8572–8578.
- 18 Ford-Hutchinson AW, Bray MA, Doig MV, Shipley ME, Smith MJ: Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. *Nature* 1980;286:264–265.
- 19 Bray MA, Ford-Hutchinson AW, Smith MJ: Leukotriene B4: an inflammatory mediator in vivo. *Prostaglandins* 1981;22:213–222.
- 20 Smith MJ, Ford-Hutchinson AW, Bray MA: Leukotriene B: a potential mediator of inflammation. *J Pharm Pharmacol* 1980;32:517–518.
- 21 Shin EH, Lee HY, Bae YS: Leukotriene B4 stimulates human monocyte-derived dendritic cell chemotaxis. *Biochem Biophys Res Commun* 2006;348:606–611.
- 22 Tager AM, Dufour JH, Goodarzi K, Bercury SD, von Andrian UH, Luster AD: BLTR mediates leukotriene B(4)-induced chemotaxis and adhesion and plays a dominant role in eosinophil accumulation in a murine model of peritonitis. *J Exp Med* 2000;192:439–446.
- 23 Goodarzi K, Goodarzi M, Tager AM, Luster AD, von Andrian UH: Leukotriene B4 and BLT1 control cytotoxic effector T cell recruitment to inflamed tissues. *Nat Immunol* 2003;4:965–973.
- 24 Tager AM, Bromley SK, Medoff BD, Islam SA, Bercury SD, Friedrich EB, Carafone AD, Gerszten RE, Luster AD: Leukotriene B4 receptor BLT1 mediates early effector T cell recruitment. *Nat Immunol* 2003;4:982–990.
- 25 Stankova J, Gagnon N, Rola-Pleszczynski M: Leukotriene B4 augments interleukin-2 receptor-beta (IL-2R beta) expression and IL-2R beta-mediated cytotoxic response in human peripheral blood lymphocytes. *Immunology* 1992;76:258–263.
- 26 Yamaoka KA, Kolb JP: Leukotriene B4 induces interleukin 5 generation from human T lymphocytes. *Eur J Immunol* 1993;23:2392–2398.
- 27 Rola-Pleszczynski M, Lemaire I: Leukotrienes augment interleukin 1 production by human monocytes. *J Immunol* 1985;135:3958–3961.
- 28 Huang L, Zhao A, Wong F, Ayala JM, Struthers M, Ujjainwalla F, Wright SD, Springer MS, Evans J, Cui J: Leukotriene B4 strongly increases monocyte chemoattractant protein-1 in human monocytes. *Arterioscler Thromb Vasc Biol* 2004;24:1783–1788.
- 29 Gaudreault E, Paquet-Bouchard C, Fiola S, Le Bel M, Lacerte P, Shio MT, Olivier M, Gosselin J: TAK1 contributes to the enhanced responsiveness of LTB(4)-treated neutrophils to Toll-like receptor ligands. *Int Immunol* 2012;24:693–704.
- 30 Kuhns DB, Nelson EL, Alvord WG, Gallin JI: Fibrinogen induces IL-8 synthesis in human neutrophils stimulated with formyl-methionyl-leucyl-phenylalanine or leukotriene B(4). *J Immunol* 2001;167:2869–2878.
- 31 Peters-Golden M, Henderson WR Jr: Leukotrienes. *N Engl J Med* 2007;357:1841–1854.
- 32 O'Driscoll BR, Cromwell O, Kay AB: Sputum leukotrienes in obstructive airways diseases. *Clin Exp Immunol* 1984;55:397–404.
- 33 Shindo K, Matsumoto Y, Hirai Y, Sumitomo M, Amano T, Miyakawa K, Matsumura M, Mizuno T: Measurement of leukotriene B4 in arterial blood of asthmatic patients during wheezing attacks. *J Intern Med* 1990;228:91–96.
- 34 Wardlaw AJ, Hay H, Cromwell O, Collins JV, Kay AB: Leukotrienes, LTC4 and LTB4, in bronchoalveolar lavage in bronchial asthma and other respiratory diseases. *J Allergy Clin Immunol* 1989;84:19–26.
- 35 Montuschi P, Kharitonov SA, Ciabattini G, Barnes PJ: Exhaled leukotrienes and prostaglandins in COPD. *Thorax* 2003;58:585–588.
- 36 McCarthy MK, Weinberg JB: Eicosanoids and respiratory viral infection: coordinators of inflammation and potential therapeutic targets. *Mediators Inflamm* 2012;2012:236345.
- 37 Gosselin J, Borgeat P: Leukotriene B4 as an antiviral and anti-neoplastic agent. *US Patent No US 5789441*.
- 38 Gosselin J, Borgeat P: Agents with leukotriene B4-like activity as antiherpes viral agents. *US Patent No US 6093741*.
- 39 Klein E, Liu A, Claesson HE: Activation of innate immunity by the leukotriene B 4 inhibits EBV induced B-cell transformation in cord blood derived mononuclear cultures. *Immunol Lett* 2008;116:174–177.
- 40 Liu A, Claesson HE, Mahshid Y, Klein G, Klein E: Leukotriene B4 activates T cells that inhibit B-cell proliferation in EBV-infected cord blood-derived mononuclear cell cultures. *Blood* 2008;111:2693–2703.
- 41 Gosselin J, Borgeat P, Flamand L: Leukotriene B4 protects latently infected mice against murine cytomegalovirus reactivation following allogeneic transplantation. *J Immunol* 2005;174:1587–1593.
- 42 Gaudreault E, Gosselin J: Leukotriene B4 induces release of antimicrobial peptides in lungs of virally infected mice. *J Immunol* 2008;180:6211–6221.
- 43 Chen N, Restivo A, Reiss CS: Leukotrienes play protective roles early during experimental VSV encephalitis. *J Neuroimmunol* 2001;120:94–102.
- 44 Coffey MJ, Phare SM, George S, Peters-Golden M, Kazanjian PH: Granulocyte colony-stimulating factor administration to HIV-infected subjects augments reduced leukotriene synthesis and anticryptococcal activity in neutrophils. *J Clin Invest* 1998;102:663–670.
- 45 Coffey MJ, Phare SM, Kazanjian PH, Peters-Golden M: 5-Lipoxygenase metabolism in alveolar macrophages from subjects infected with the human immunodeficiency virus. *J Immunol* 1996;157:393–399.
- 46 Bertin J, Barat C, Belanger D, Tremblay MJ: Leukotrienes inhibit early stages of HIV-1 infection in monocyte-derived microglia-like cells. *J Neuroinflammation* 2012;9:55.
- 47 Trindade BC, Sorgi CA, Nicolette LD, Malta TM, Pinto MT, Takayanagui OM, Covas DT, Filho OA, Kashima S, Faccioli LH: Leukotrienes are upregulated and associated with human T-lymphotropic virus type 1 (HTLV-1)-associated neuroinflammatory disease. *PLoS One* 2012;7:e51873.
- 48 Qiu H, Straat K, Rahbar A, Wan M, Soderberg-Naucler C, Haeggstrom JZ: Human CMV infection induces 5-lipoxygenase expression and leukotriene B4 production in vascular smooth muscle cells. *J Exp Med* 2008;205:19–24.
- 49 Peters-Golden M, Canetti C, Mancuso P, Coffey MJ: Leukotrienes: underappreciated mediators of innate immune responses. *J Immunol* 2005;174:589–594.
- 50 Demitsu T, Katayama H, Saito-Taki T, Yaoita H, Nakano M: Phagocytosis and bactericidal action of mouse peritoneal macrophages treated with leukotriene B4. *Int J Immunopharmacol* 1989;11:801–808.
- 51 Bailie MB, Standiford TJ, Laichalk LL, Coffey MJ, Strieter R, Peters-Golden M: Leukotriene-deficient mice manifest enhanced lethality from Klebsiella pneumonia in association with decreased alveolar macrophage phagocytic and bactericidal activities. *J Immunol* 1996;157:5221–5224.
- 52 Malaviya R, Abraham SN: Role of mast cell leukotrienes in neutrophil recruitment and bacterial clearance in infectious peritonitis. *J Leukoc Biol* 2000;67:841–846.
- 53 Medeiros AI, Sa-Nunes A, Soares EG, Peres CM, Silva CL, Faccioli LH: Blockade of endogenous leukotrienes exacerbates pulmonary histoplasmosis. *Infect Immun* 2004;72:1637–1644.
- 54 De Smet K, Contreras R: Human antimicrobial peptides: defensins, cathelicidins and histatins. *Biotechnol Lett* 2005;27:1337–1347.

- 55 Gaudreault E, Gosselin J: Leukotriene B4-mediated release of antimicrobial peptides against cytomegalovirus is BLT1 dependent. *Viral Immunol* 2007;20:407–420.
- 56 Kawai T, Akira S: The roles of TLRs, RLRs and NLRs in pathogen recognition. *Int Immunol* 2009;21:317–337.
- 57 Serezani CH, Lewis C, Jancar S, Peters-Golden M: Leukotriene B4 amplifies NF-kappaB activation in mouse macrophages by reducing SOCS1 inhibition of MyD88 expression. *J Clin Invest* 2011;121:671–682.
- 58 Gaudreault E, Gosselin J: Leukotriene B4 potentiates CpG signaling for enhanced cytokine secretion by human leukocytes. *J Immunol* 2009;183:2650–2658.
- 59 Flamand L, Borgeat P, Lalonde R, Gosselin J: Release of anti-HIV mediators after administration of leukotriene B4 to humans. *J Infect Dis* 2004;189:2001–2009.
- 60 Widegren H, Andersson M, Borgeat P, Flamand L, Johnston S, Greiff L: LTB4 increases nasal neutrophil activity and conditions neutrophils to exert antiviral effects. *Respir Med* 2011;105:997–1006.
- 61 Study report: 'LTB4 results revealed' (CTN 213). Connections, The Quarterly Newsletter of The Canadian HIV Trials Network 2007; 18:2.
- 62 Konstan MW, Doring G, Lands LC, Hilliard KA, Koker P, Bhattacharya S, Staab A, Hamilton AL, on behalf of the Investigators and Coordinators of BI Trial 543.45: Results of a phase II clinical trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of CF lung disease. *Pediatr Pulmonol* 2005;40:125–126.
- 63 Schmidt HH, Seifert R, Bohme E: Formation and release of nitric oxide from human neutrophils and HL-60 cells induced by a chemotactic peptide, platelet activating factor and leukotriene B4. *FEBS Lett* 1989;244:357–360.
- 64 Larfars G, Lantoine F, Devynck MA, Palmblad J, Gyllenhammar H: Activation of nitric oxide release and oxidative metabolism by leukotrienes B4, C4, and D4 in human polymorphonuclear leukocytes. *Blood* 1999;93:1399–1405.
- 65 Li Y, Ferrante A, Poulos A, Harvey DP: Neutrophil oxygen radical generation. Synergistic responses to tumor necrosis factor and mono/polyunsaturated fatty acids. *J Clin Invest* 1996;97:1605–1609.
- 66 Rae SA, Smith MJ: The stimulation of lysosomal enzyme secretion from human polymorphonuclear leucocytes by leukotriene B4. *J Pharm Pharmacol* 1981;33:616–617.
- 67 Mancuso P, Nana-Sinkam P, Peters-Golden M: Leukotriene B4 augments neutrophil phagocytosis of *Klebsiella pneumoniae*. *Infect Immun* 2001;69:2011–2016.
- 68 Dewald B, Baggiolini M: Activation of NADPH oxidase in human neutrophils. Synergism between fMLP and the neutrophil products PAF and LTB4. *Biochem Biophys Res Commun* 1985;128:297–304.
- 69 Serhan CN, Radin A, Smolen JE, Korchak H, Samuelsson B, Weissmann G: Leukotriene B4 is a complete secretagogue in human neutrophils: a kinetic analysis. *Biochem Biophys Res Commun* 1982;107:1006–1012.
- 70 Flamand L, Tremblay MJ, Borgeat P: Leukotriene B4 triggers the in vitro and in vivo release of potent antimicrobial agents. *J Immunol* 2007;178:8036–8045.
- 71 Teixeira MM, Cunha FQ, Noronha-Dutra A, Hothersall J: Production of singlet oxygen by eosinophils activated in vitro by C5a and leukotriene B4. *FEBS Lett* 1999;453:265–268.
- 72 Lindsay MA, Giembycz MA: Signal transduction and activation of the NADPH oxidase in eosinophils. *Mem Inst Oswaldo Cruz* 1997; 92(suppl 2):115–123.
- 73 Perkins RS, Lindsay MA, Barnes PJ, Giembycz MA: Early signalling events implicated in leukotriene B4-induced activation of the NADPH oxidase in eosinophils: role of Ca2+, protein kinase C and phospholipases C and D. *Biochem J* 1995;310:795–806.
- 74 Talvani A, Machado FS, Santana GC, Klein A, Barcelos L, Silva JS, Teixeira MM: Leukotriene B(4) induces nitric oxide synthesis in *Trypanosoma cruzi*-infected murine macrophages and mediates resistance to infection. *Infect Immun* 2002;70:4247–4253.
- 75 Wirth JJ, Kierszenbaum F: Stimulatory effects of leukotriene B4 on macrophage association with and intracellular destruction of *Trypanosoma cruzi*. *J Immunol* 1985;134:1989–1993.
- 76 Mancuso P, Standiford TJ, Marshall T, Peters-Golden M: 5-Lipoxygenase reaction products modulate alveolar macrophage phagocytosis of *Klebsiella pneumoniae*. *Infect Immun* 1998; 66:5140–5146.
- 77 Soares EM, Mason KL, Rogers LM, Serezani CH, Faccioli LH, Aronoff DM: Leukotriene B4 enhances innate immune defense against the puerperal sepsis agent *Streptococcus pyogenes*. *J Immunol* 2013;190:1614–1622.
- 78 Serezani CH, Aronoff DM, Jancar S, Mancuso P, Peters-Golden M: Leukotrienes enhance the bactericidal activity of alveolar macrophages against *Klebsiella pneumoniae* through the activation of NADPH oxidase. *Blood* 2005;106:1067–1075.
- 79 Dugas B, Paul-Eugene N, Cairns J, Gordon J, Calenda A, Mencia-Huerta JM, Braquet P: Leukotriene B4 potentiates the expression and release of Fc epsilon RII/CD23, and proliferation and differentiation of human B lymphocytes induced by IL-4. *J Immunol* 1990; 145:3406–3411.
- 80 Yamaoka KA, Claesson HE, Rosen A: Leukotriene B4 enhances activation, proliferation, and differentiation of human B lymphocytes. *J Immunol* 1989;143:1996–2000.